Santhera Appoints Dr. Oliver P. Kronenberg as Chief Legal Officer and Company Secretary
2024年7月31日 - 2:00PM
- Dr. Kronenberg
brings 25 years of legal experience, with 20 years in the
pharmaceutical industry
- Oliver Strub
appointed as Head of Compliance
Pratteln, Switzerland, July 31,
2024 – Santhera Pharmaceuticals (SIX: SANN) announces the Board of
Directors has appointed Dr. Oliver P. Kronenberg as Chief Legal
Officer and Corporate Secretary of Santhera Pharmaceuticals AG,
effective August 1, 2024.
As a member of the executive management team,
Dr. Oliver P. Kronenberg will lead the Company's legal strategy and
global legal activities, including transactions, corporate
governance, and IP. He succeeds Oliver Strub, who remains at
Santhera and will assume the newly created role of Head of
Compliance, where he will be responsible for overseeing the
development, implementation and management of Santhera’s compliance
program.
“We are pleased to welcome Oliver to Santhera as
Chief Legal Officer and as a member of our executive leadership
team,” commented Dr. Thomas Meier, Chairman of the Board of
Santhera. “His expertise and achievements in key legal
areas of the life sciences industry strengthens our leadership
team, increasing our expertise in corporate governance and
knowledge in the approval and market launch of pharmaceutical
products. We extend our deepest thanks to Oliver Strub, who has led
Santhera’s legal department since 2006 and will continue as Head of
Compliance, where his focus will be on overseeing Santhera’s
compliance program.”
Dr. Oliver P. Kronenberg is a lawyer with more
than 25 years of experience, including over 20 years in the
international pharmaceutical industry. Since 2008 he has worked in
various roles at Vifor Pharma and its parent company, Galenica. As
Head of Legal and Compliance at Vifor Pharma, he was responsible
for establishing the legal, IP, and compliance department. In 2013,
he was promoted to Group General Counsel of Galenica. After the
split of the Galenica Group in April 2017, he returned to Vifor
Pharma, becoming Group General Counsel and was appointed member of
the executive committee in 2022. Dr. Kronenberg has supported
Santhera since April 2024 as interim General Counsel.
Dr. Oliver P. Kronenberg
commented: “I am excited to be joining Santhera at
this important stage of its development, as momentum builds towards
the continuous launch of AGAMREE® (vamorolone) for the treatment of
Duchenne muscular dystrophy. I look forward to working closely with
the executive team and the Board in the months ahead.”
Dr. Kronenberg holds a doctorate in law from the
University of Basel, an LL.M. degree from the College of Europe in
Bruges, Belgium, a degree in Finance for Executives from INSEAD,
and an IMD Board Director Diploma.
About SantheraSanthera
Pharmaceuticals (SIX: SANN) is a Swiss specialty pharmaceutical
company focused on the development and commercialization of
innovative medicines for rare neuromuscular and pulmonary diseases
with high unmet medical need. The Company has an exclusive license
from ReveraGen for all indications worldwide to AGAMREE®
(vamorolone), a dissociative steroid with novel mode of action,
which was investigated in a pivotal study in patients with Duchenne
muscular dystrophy (DMD) as an alternative to standard
corticosteroids. AGAMREE for the treatment of DMD is approved in
the U.S. by the Food and Drug Administration (FDA), in the EU by
the European Medicines Agency (EMA), and in the UK by the Medicines
and Healthcare products Regulatory Agency (MHRA). Santhera has
out-licensed rights to vamorolone for North America to Catalyst
Pharmaceuticals and for China to Sperogenix Therapeutics. For
further information, please visit www.santhera.com.
AGAMREE® is a trademark of Santhera
Pharmaceuticals.
For further information please
contact: public-relations@santhera.com orEva Kalias, Head
Investor Relations & CommunicationsPhone: +41 79 875 27
80eva.kalias@santhera.com
Disclaimer / Forward-looking
statements This communication does not constitute an offer
or invitation to subscribe for or purchase any securities of
Santhera Pharmaceuticals Holding AG. This publication may contain
certain forward-looking statements concerning the Company and its
business. Such statements involve certain risks, uncertainties and
other factors which could cause the actual results, financial
condition, performance or achievements of the Company to be
materially different from those expressed or implied by such
statements. Readers should therefore not place undue reliance on
these statements, particularly not in connection with any contract
or investment decision. The Company disclaims any obligation to
update these forward-looking statements.
# # #